KardiaMobile 6L for measuring cardiac QT interval in people having antipsychotic medication
Closed for comments This consultation ended on at Request commenting lead permission
4 Evidence generation recommendations
4.1 Further evidence generation is recommended on:
the effectiveness (diagnostic accuracy) of using KardiaMobile 6L to measure QT interval in people having or about to have antipsychotic medications and the effect of the corrected QT interval (QTc) result on clinical decision making
how many people having antipsychotic medication choose to have their QT interval measured using KardiaMobile 6L when it is offered as an alternative to 12-lead electrocardiogram (ECG)
how long it takes to do the test and get the QT interval result using KardiaMobile 6L and a 12-lead device (including set up, ECG recording, QT measurement and correction calculation, reporting time)
how often are ECGs interpreted by different healthcare professionals (for example a psychiatrist or a cardiologist), and by different services (for example locally by the healthcare professional recording the ECG or making the treatment decision, or by a centralised service) when using KardiaMobile 6L and a 12-lead device
how often is QT interval measurement repeated using a 12-lead device after using KardiaMobile 6L and why (for example because of an abnormal QTc result on KardiaMobile 6L, QT interval not measurable from KardiaMobile 6L ECG or technical failure)
how long it takes before antipsychotic medication is started, whether having an ECG delays this and whether any treatment changes are made after the ECG result
how many people who need an ECG to measure QT interval for having antipsychotic medication have one
how common prolonged QT is in people having antipsychotics.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions